New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
06:42 EDTMYL, ABT, MDT, COV, VRX, AGNObama to look to limit inversion deals, Politico says
President Obama yesterday said that his administration would seek to "at least discourage" tax inversion deals, according to Politico. The administration wants to move quickly on this initiative, the website quoted the president as saying. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Allergan (AGN). Reference Link
News For MYL;ABT;MDT;COV;VRX;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 9, 2014
06:47 EDTAGNAllergan sees FY14 non-GAAP EPS $6.20-$6.25, consensus $5.81
Subscribe for More Information
06:46 EDTAGNAllergan raises Q3 EPS to $1.76-$1.78 from $1.44-$1.47, consensus $1.48
Expects Q3 product net sales to increase in excess of 17% in dollars compared to product net sales from 3Q13.
October 8, 2014
16:10 EDTAGNAllergan initiated with a Buy at Deutsche Bank
Subscribe for More Information
10:46 EDTCOVOptions with decreasing implied volatility
Subscribe for More Information
08:42 EDTAGNSalix shares should be bought on weakness, says Sterne Agee
After Reuters yesterday afternoon reported that Actavis (ACT) plans to make a new merger approach to Allergan (AGN), Sterne Agee believes that Salix's standalone value is $162. The firm expects the shares to reach that level following approval of its Xifaxan IBS-D drug after the February 2015 PDUFA date.
07:19 EDTAGNCBI to hold a conference
Subscribe for More Information
06:47 EDTMYLLawmakers may push for new regulations on generic drug makers, NY Times says
After the prices of some generic drugs soared more than 1,000% over the last year, two influential members of Congress are probing the sector and threatening to look to impose new regulations on it, according to The New York Times. Generic drug makers include Teva (TEVA), Mylan (MYL), Actavis (ACT), and Lannett (LCI).Reference Link
06:23 EDTAGN, VRXActavis more inclined to pursue Allergan over Salix, says Citigroup
Subscribe for More Information
October 7, 2014
18:29 EDTAGN, VRXOn The Fly: After Hours Movers
Subscribe for More Information
18:05 EDTVRX, AGNValeant, Pershing Square plan to raise Allergan bid by $15 a share, WSJ says
Subscribe for More Information
17:52 EDTAGN, VRXAllergan up 2.8% after Dow Jones says Valeant planning to boost bid for company
17:49 EDTAGN, VRXValeant up 3.9% after Dow Jones says planning to boost Allergan bid
Subscribe for More Information
17:47 EDTAGN, VRXValeant, Pershing Square planning to boost Allergan bid by $15 a share, DJ says
Subscribe for More Information
15:21 EDTVRX, AGNAllergan warms to sale as Actavis plans new approach, Reuters says
Subscribe for More Information
15:01 EDTAGNAllergan up 1.5% following report on Actavis planned approach on merger
14:59 EDTAGNActavis plans new approach to Allergan, Reuters reports
Subscribe for More Information
10:56 EDTMYLOptions with increasing implied volatility
Subscribe for More Information
10:43 EDTCOVOptions with decreasing implied volatility
Subscribe for More Information
07:48 EDTAGNSalix reinstated with a Buy at Jefferies
Subscribe for More Information
07:12 EDTAGN, VRXAllergan requests Ackman be hindered from voting at meeting, Bloomberg says
In an effort to avoid an unsolicited $54B acquisition offer from Valeant Pharmaceuticals (VRX), Allergan (AGN) filed a request in a California court for a judge to hinder Bill Ackmanís Pershing Square from voting its 10% stake at the December shareholder meeting, according to Bloomberg, citing the filing. A hearing regarding Allergan's request is set to occur on October 28. Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use